Edralbrutinib Completed Phase 2 Trials for Neuromyelitis Optica Spectrum Disorders Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04670770An Open Label Study of the Effects of SHR1459 in NMOSDs Patients